Cargando…

Atypical hemolytic uremic syndrome (aHUS) responsive to mycophenolate mofetil: A case report from Nepal

INTRODUCTION: An atypical hemolytic uremic syndrome is an extremely rare and life-threatening thrombotic microangiopathy. This disorder is caused by dysregulation of the alternative pathway of the complement system in association with genetic abnormalities or the development of autoantibodies. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gurung, Jyoti, Regmi, Anil, Poudel, Bilash, Poudel, Ritu, Sharma, Rituraj, Pradhan, Sandip Raj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793206/ https://www.ncbi.nlm.nih.gov/pubmed/36582885 http://dx.doi.org/10.1016/j.amsu.2022.104932

Ejemplares similares

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
por: Fakhouri, Fadi, et al.
Publicado: (2021)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011)

Baseline characteristics and evolution of Brazilian patients with atypical hemolytic uremic syndrome: first report of the Brazilian aHUS Registry
por: Vaisbich, Maria Helena, et al.
Publicado: (2022)

Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry
por: Halimi, Jean-Michel, et al.
Publicado: (2022)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Atypical Hemolytic Uremic Syndrome (aHUS) and Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)—Two Diseases That Exacerbate Each Other: Case Report
por: Bogdał, Anna, et al.
Publicado: (2021)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
por: Yenerel, Mustafa N.
Publicado: (2014)

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J., et al.
Publicado: (2022)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Compound Haplotype Variants in CFH and CD46 Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)—A Series of Cases from a Single Family
por: Furmańczyk-Zawiska, Agnieszka, et al.
Publicado: (2021)

Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J, et al.
Publicado: (2023)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016)

aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2010)

The global aHUS registry: methodology and initial patient characteristics
por: Licht, Christoph, et al.
Publicado: (2015)

Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life
por: Legendre, Christophe, et al.
Publicado: (2021)

Relevance of Bacteriophage 933W in the Development of Hemolytic Uremic Syndrome (HUS)
por: Del Cogliano, Manuel E., et al.
Publicado: (2018)

Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
por: Scheiring, Johanna, et al.
Publicado: (2008)

Erratum to: aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2012)

Can eculizumab be discontinued in aHUS?: Case report and review of the literature
por: Sahutoglu, Tuncay, et al.
Publicado: (2016)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
por: Lokki, A. Inkeri, et al.
Publicado: (2020)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?
por: Spasiano, Andrea, et al.
Publicado: (2023)

Knowledge, attitude and reported practice regarding donning and doffing of personal protective equipment among frontline healthcare workers against COVID-19 in Nepal: A cross-sectional study
por: Pandey, Sagar, et al.
Publicado: (2021)

Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS)
por: Goldwater, Paul N, et al.
Publicado: (2012)

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
por: Manière, Louis, et al.
Publicado: (2019)

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS
por: Valoti, Elisabetta, et al.
Publicado: (2019)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

Atypical hemolytic uremic syndrome
por: Loirat, Chantal, et al.
Publicado: (2011)

Atypical Hemolytic Uremic Syndrome
por: Kavanagh, David, et al.
Publicado: (2013)

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
por: Bouwmeester, Romy N., et al.
Publicado: (2022)

Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS)
por: Loos, Sebastian, et al.
Publicado: (2021)

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification
por: Martín Merinero, Hector, et al.
Publicado: (2021)

Pathogenesis of Atypical Hemolytic Uremic Syndrome
por: Yoshida, Yoko, et al.
Publicado: (2019)

The genetics of atypical hemolytic uremic syndrome
por: Feitz, Wouter J. C., et al.
Publicado: (2018)

Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry
por: Greenbaum, Larry A., et al.
Publicado: (2020)

Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis
por: Klämbt, Verena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fgg05dv3nclguguuam3bi23pg4